SpectraScience, Inc
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
SpectraScience, Inc - overview
Location
San Diego, CA, US
Primary Industry
Medical Devices & Equipment
About
SpectraScience, Inc. is focused on developing advanced optical technologies for medical diagnostics, particularly in gastroenterology, utilizing innovative light-based systems to enhance disease detection and improve patient care outcomes. Founded in San Diego, US, SpectraScience, Inc. specializes in optical technologies for the medical field, particularly diagnostic imaging.
The company has experienced strategic pivots towards enhancing its product offerings. Its latest funding round was a Venture Debt of USD 0. 50 mn raised on September 25, 2013, contributing to a total funding of USD 3. 15 mn.
The company has undertaken 7 deals in its operational history. SpectraScience, Inc. specializes in advanced optical technologies for the medical and scientific communities, focusing on diagnostic imaging and therapeutic devices. Their proprietary systems, utilizing light-based technologies, enhance disease diagnosis, especially in gastroenterology, thereby improving accuracy for healthcare professionals.
They serve hospitals and clinics across North America and Europe, with a focus on the United States, Germany, and the United Kingdom, facilitating improved patient outcomes through their clinical solutions. In 2016, SpectraScience reported revenue of USD 5,150,000 and an EBITDA loss of USD 1,653,689. The company generates revenue primarily through direct sales to healthcare institutions and partnerships with medical device distributors. Transactions typically involve sales of diagnostic systems and consumables, structured around one-time purchases combined with ongoing support and service contracts, fostering long-term relationships with healthcare providers.
Following the recent debt funding raised in September 2013, SpectraScience, Inc. intends to leverage these funds to accelerate the development of new diagnostic products and expand into international markets. Plans are underway to enhance their product line for better functionality and ease of use. The focus is on expanding their reach into European and Asian markets by 2025, aiming to establish a more global presence in the medical diagnostics space.
Primary Industry
Medical Devices & Equipment
Sub Industries
Medical Devices & Equipment, Biomaterials
Website
www.spectrascience.com
Verticals
HealthTech
Total Amount Raised
Subscriber access only
SpectraScience, Inc - financials
| Fiscal Year Ended | Dec 31, 2008 | Dec 31, 2009 | Dec 31, 2010 | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 60,560 | 167,123 | 23,650 | 26,735 | 461,296 | 240,000 | - | - | - |
| % Revenue Growth (YoY) | - | 176.0% | (85.8%) | 13.0% | 1625.4% | (48.0%) | - | - | - |
| EBITDA (USD) | (4,989,738) | (4,005,040) | (3,624,390) | (4,457,064) | 253,446 | (492,604) | - | - | - |
| Operating Income (USD) | (5,271,332) | (4,436,812) | (4,098,036) | (4,767,591) | (4,320,772) | (2,731,710) | - | - | - |
| Operating Margin | (8704.3%) | (2654.8%) | (17327.8%) | (17832.8%) | (936.7%) | (1138.2%) | - | - | - |
| % EBITDA Margin | (8239.3%) | (2396.5%) | (15325.1%) | (16671.3%) | 54.9% | (205.3%) | - | - | - |
| NET Income (USD) | (5,144,902) | (4,432,187) | (4,098,622) | (4,762,111) | (9,092,598) | (2,749,645) | - | - | - |
| % Net Margin | (8495.5%) | (2652.1%) | (17330.3%) | (17812.3%) | (1971.1%) | (1145.7%) | - | - | - |
SpectraScience, Inc - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.